Modern Vaccines

Manufacturing, Bottlenecks, from DNA to product

30 August 2022

A one day science
symposium

at the EPFL SwissTech Convention Center, Lausanne, Switzerland

Talks & discussion
with amazing speakers

Including Patrick Soon-Shiong, Rino Rappuoli, Jamie Triccas, Michael Watson, Paco Pino, Maria Wurm and Florian Wurm

You’re
invited!

Join us for a day of talks,
discussion and networking.
Register your interest now,
as seats have limited availability.

Event mission

Our world needs innovation in vaccine manufacturing

Making vaccines and therapeutic products for the world is a highly complex enterprise. The COVID-19 pandemic has shown a great need for science and technology to quickly develop effective and affordable solutions.

For protein-based therapeutics and prophylactic agents, from DNA to product, poor manufacturability is one of the major bottlenecks that prevents great ideas from making it to the clinic and market.

ExcellGene aims to bring people together to discuss these bottlenecks and challenges: top scientists, thought leaders, regulatory experts, investors and political representatives, covering industry and academia.

On August  30th 2022, meet us in Lausanne, Switzerland for a one-day (free of cost!) symposium of talks, discussion and networking.

Let us reflect, learn, push for innovation and remove barriers, and thus pave the way for modern and efficient approaches in developing vaccines and therapeutics on a global scale.

A different kind of scientific

symposium

Conferences on bioprocessing for biological products often seem to miss the main reasons why manufacturability is a key factor that hinders progress to clinical trials.

Good ideas are not lacking, but getting things done is cumbersome. To explore and ensure effective
discussion on the subject, this symposium will focus on:

Getting all sides of the story: a pragmatic view 
Bringing together people that share their experience across industry, academia, regulatory, politicians …etc.

Problem-solving through lively discussion
By engaging everyone in the discussion, we aim to get answers to complex questions, balancing opportunities and risks.

Starting open questions / issues to tackle 

  1. Manufacturing of protein-based antigen from clonally derived cell lines?
  2. Needs to show removal of theoretical virus load from CHO cells that never had an issue with virus loads in harvests of cell culture?
  3. Proof of clonality: an unnecessary exercise due to misunderstanding by regulatory examiners?
  4. Purity in antigen preparations for recombinant vaccines: how far must we go?
  5. Cell line stability studies: 3 month of wasted time?
  6. FiM studies with microgram-quantities of protein, do we need non-human primate studies first?

The speakers

Meet the speakers

Prof. Dr. Med.
Patrick Soon-Shiong
Immunity Bio,
Nant-Group
and Philantrophist

Biography

Prof. Dr. Med.
Rino Rappuoli
GSK Vaccines

Biography

Prof. Dr. James Triccas
Sydney University,
Prof. of Medical Microbiology

Biography

Dr. Michael Watson
CEO MEVOX Ltd.

and Executive Chair
VaxEquity Ltd.

Biography

Dr. Paco Pino,
Director R+D,
ExcellGene SA

Biography

Dr. Maria J. Wurm
Co-founder, CEO
ExcellGene SA

Biography

Prof. em. Dr, 
Florian M. Wurm
Co-founder,
CSO ExcellGene SA

Biography

Prof. Dr. Med.
Patrick Soon-Shiong
Immunity Bio,
Nant-Group
and Philantrophist

Prof. Dr. Med.
Rino Rappuoli
GSK Vaccines

Prof. Dr.
James Triccas

Sydney University,
Prof. of Medical Microbiology

Dr. Michael Watson
CEO MEVOX Ltd.
and Executive Chair
VaxEquity Ltd.

Dr. Paco Pino,
Director R+D,
ExcellGene SA

Dr. Maria J. Wurm
Co-founder, CEO
ExcellGene SA

Prof. em. Dr 
Florian M. Wurm
Co-founder,
CSO ExcellGene SA

Prof. Dr. Med.
Patrick Soon-Shiong
Immunity Bio,
Nant-Group
and Philantrophist

Prof. Dr. Med.
Rino Rappuoli
GSK Vaccines

Prof. Dr.
James Triccas

Sydney University,
Prof. of Medical Microbiology

Dr. Michael Watson
CEO MEVOX Ltd.
and Executive Chair
VaxEquity Ltd.

Biography

Biography

Biography

Biography

Dr. Paco Pino,
Director R+D,
ExcellGene SA

Biography

 Dr. Maria J. Wurm
Co-founder, CEO
ExcellGene SA

Biography

Prof. em. Dr,  Florian M. Wurm
Co-founder,
CSO ExcellGene SA

Biography

Vaccines Manufacturing

A Commentary Paper

“Affordable SARS-Cov-2 protein vaccines
for the pandemic endgame”

Affordable-SARS-CoV-2-protein-vaccines...

At a glance

Key Facts

An exceptional and unique one-day symposium

August 30th, SwissTech Convention Center
Lausanne Switzerland

Manufacturing Science in Pharma/Biotech

A neglected topic in Research 
Non-commercial

ONLY 250 seats available

 A meeting with in-person attendance 

Outstanding thought leaders in academia and industry

 Share their view and insights

Celebration of 20 years of ExcellGene

From a one employee EPFL
spin-off to an international service
company (DNA-product)

No cost for registration, lunch and cocktail

 Great discussion and networking opportunity. Students very welcome!

Venue

EPFL SwissTech Convention Center,
Lausanne, Switzerland

Event information

Day program

Venue

EPFL Swisstech Convention Center